BHLHE40: A Potential Drug Target and Biomarker (G8553)

Target Name: BHLHE40

NCBI ID: G8553

BHLHE40

BHLHE40: A Potential Drug Target and Biomarker

Skin is an essential organ that plays a critical role in maintaining the integrity of the body's barrier system. It is responsible for protecting the body from external threats, such as pathogens, environmental factors, and solar radiation. The skin is also responsible for regulating the body's temperature and storing a variety of substances, including water, electrolytes, and waste products.

One of the proteins that helps maintain the skin's integrity is BHLHE40 (Enhancer-of-split and hairy-related protein 2). This protein is expressed in high levels in various tissues of the body, including the skin, hair, and nervous system. It is involved in a variety of physiological processes that are essential for maintaining the health and function of these tissues, including cell growth, differentiation, and inflammation.

Despite the critical role of BHLHE40 in maintaining the skin's integrity, the protein has not yet been fully understood or targeted as a drug. However, recent studies have identified potential drug targets and biomarkers for BHLHE40.

One potential drug target for BHLHE40 is the protein known as SMAD4. SMAD4 is a transcription factor that is involved in regulating gene expression and has been shown to play a role in a variety of diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. It is possible that BHLHE40 may be a target for SMAD4 because it is known to interact with the protein in a similar way.

Another potential drug target for BHLHE40 is the protein known as NF-kappa-B. NF-kappa-B is a signaling pathway that is involved in a variety of cellular processes, including inflammation, pain, and survival. BHLHE40 has been shown to interact with the NF-kappa-B protein, which may make it a potential target forNF-kappa-B inhibitors.

In addition to potential drug targets, BHLHE40 has also been identified as a potential biomarker for a variety of skin diseases. For example, BHLHE40 has been shown to be expressed in the skin and has been associated with a variety of skin conditions, including eczema, psoriasis, and dermatitis. It is possible that BHLHE40 may be a useful biomarker for these conditions and could be used as a target for diagnostic tests or therapies.

Overall, BHLHE40 is a protein that is involved in a variety of physiological processes that are essential for maintaining the health and function of the skin. While it is still too early to determine its full role in the body, recent studies have identified potential drug targets and biomarkers for BHLHE40. Further research is needed to fully understand its functions and potential uses in medicine.

Protein Name: Basic Helix-loop-helix Family Member E40

Functions: Transcriptional repressor involved in the regulation of the circadian rhythm by negatively regulating the activity of the clock genes and clock-controlled genes (PubMed:12397359, PubMed:18411297). Acts as the negative limb of a novel autoregulatory feedback loop (DEC loop) which differs from the one formed by the PER and CRY transcriptional repressors (PER/CRY loop) (PubMed:14672706). Both these loops are interlocked as it represses the expression of PER1/2 and in turn is repressed by PER1/2 and CRY1/2 (PubMed:15193144). Represses the activity of the circadian transcriptional activator: CLOCK-BMAL1|BMAL2 heterodimer by competing for the binding to E-box elements (5'-CACGTG-3') found within the promoters of its target genes (PubMed:15560782). Negatively regulates its own expression and the expression of DBP and BHLHE41/DEC2 (PubMed:14672706). Acts as a corepressor of RXR and the RXR-LXR heterodimers and represses the ligand-induced RXRA and NR1H3/LXRA transactivation activity (PubMed:19786558). May be involved in the regulation of chondrocyte differentiation via the cAMP pathway (PubMed:19786558). Represses the transcription of NR0B2 and attentuates the transactivation of NR0B2 by the CLOCK-BMAL1 complex (PubMed:28797635). Drives the circadian rhythm of blood pressure through transcriptional repression of ATP1B1 in the cardiovascular system (PubMed:30012868)

The "BHLHE40 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about BHLHE40 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets